Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
An article from
Dive Brief
//
Obesity drugs
Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
The drug company said Wednesday that it planned to file lawsuits against US businesses that sell retatrutide products illegally,…
The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss…
The lawsuits target a range of businesses that allegedly marketed retatrutide products to consumers despite the drug remaining…
Knockoff versions of the company's weight-loss drug raise concerns, citing a "public health crisis."
The drug remains in Phase 3 clinical trials and has not been approved by any regulator for human use
Eli Lilly sued six US compounding pharmacies for illegally selling unapproved retatrutide.
